After scoring an early authorization for its COVID-19 therapy remdesivir, Gilead Sciences has been on the hunt for manufacturing partners to help boost production. Through a series of licensing agreements with generics makers, Gilead has taken the first …
See Original Article

Nearly four years removed from a disastrous sales fraud probe and an overhaul of its senior leadership, Alexion has launched a campaign to bolster its rare disease pipeline through pricey acquisitions. But one activist investor thinks Alexion’s strategy is …
See Original Article

Treasury yields were little changed Tuesday, following a rise in the previous session, as investors awaited U.S. consumer inflation data which is expected to see another fall in prices in April. hat are Treasurys doing? The 10-year Treasury note yield …
See Original Article

In a landmark acknowledgment of the toll that content moderation takes on its workforce, Facebook has agreed to pay $52 million to current and former moderators to compensate them for mental health issues developed on the job. In a preliminary settlement …
See Original Article

Mae Davis sat in her red four-door sedan in the parking lot of the Valley Hills Mall on Tuesday, took a bite out of her sandwich with a satisfying crunch and waited. She drove from Statesville to buy a pair of sheets for her double bed. None of the department …
See Original Article